Forte Biosciences: 2026 Is Major Inflection Point For FB102
Source: SeekingAlpha
2026-04-10 15:27:12 ET
I'm initiating Forte Biosciences ( FBRX ) with a "Hold" rating. The reason why I'm doing so is because even though in the past it had a rough failure with another candidate by the name of FB401 it might be able to potentially recover with another candidate that it has been working on. In essence, it failed to meet the primary endpoint of a phase 2 study using live biotherapeutic FB-401 for the treatment of patients with atopic dermatitis [AD]. This caused the company to get rid of this program from its pipeline....
Read the full article on Seeking Alpha
For further details see:
Forte Biosciences: 2026 Is Major Inflection Point For FB102
AnaptysBio Inc.
NASDAQ: ANAB
ANAB Trading
-0.85% G/L:
$51.41 Last:
141,198 Volume:
$50.58 Open:
ANAB Latest News
April 20, 2026 09:15:00 am
Anaptys Completes Separation of First Tracks Biotherapeutics and Now Exclusively Manages GSK and Vanda Financial Collaborations
March 27, 2026 09:00:00 am
Anaptys Board of Directors Approves Spin-Off of First Tracks Biotherapeutics
March 27, 2026 09:00:00 am
First Tracks Biotherapeutics, the Planned Spin-Off of Anaptys, Secures Commitments of $145 Million in Private Placement
March 27, 2026 09:00:00 am
Anaptys Announces $100 Million Stock Repurchase Plan and Provides a Business Update
ANAB Stock Data
$1,401,175,024
18,412,833
0.27%
71
N/A
Biotechnology & Life Sciences
Healthcare
US
San Diego
